Patents by Inventor Benedikt Timmerman

Benedikt Timmerman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9486524
    Abstract: The present invention relates to a composition for eliciting a specific cytotoxic T lymphocyte (CTL) response against T cell epitopes in a mammal, which comprises a compound provoking lymphocytopenia, a molecule having selective affinity for professional antigen presenting cells (APC), wherein said molecule is associated to said T cell epitope, and optionally, a pharmaceutical acceptable carrier. Advantageously, the composition further contains an adjuvant. Said composition may be used in anti-infections and anti-cancer therapies.
    Type: Grant
    Filed: August 31, 2007
    Date of Patent: November 8, 2016
    Assignee: GENTICEL
    Inventors: Xavier Preville, Benedikt Timmerman
  • Patent number: 9387243
    Abstract: The invention relates to a recombinant protein comprising one or several polypeptides bearing one or several epitopes of one or several HPV antigens, said polypeptides being inserted in the same or different permissive sites of an adenylate cyclase (CyaA) protein or of a fragment thereof, wherein said CyaA fragment retains the property of said adenylate cyclase protein to target Antigen Presenting Cells. It also concerns polynucleotides encoding the same. The recombinant protein or the polynucleotide can be used for the design of therapeutic means against HPV infection or against its malignant effects.
    Type: Grant
    Filed: December 16, 2013
    Date of Patent: July 12, 2016
    Assignees: Institut Pasteur, Institut National de la Sante et de la Recherche Medicale, Centre National de la Recherche Scientifique, Genticel
    Inventors: Xavier-Edmond-Edouard Preville, Claude Leclerc, Daniel Ladant, Benedikt Timmerman
  • Publication number: 20140227308
    Abstract: The invention relates to a recombinant protein comprising one or several polypeptides bearing one or several epitopes of one or several HPV antigens, said polypeptides being inserted in the same or different permissive sites of an adenylate cyclase (CyaA) protein or of a fragment thereof, wherein said CyaA fragment retains the property of said adenylate cyclase protein to target Antigen Presenting Cells. It also concerns polynucleotides encoding the same. The recombinant protein or the polynucleotide can be used for the design of therapeutic means against HPV infection or against its malignant effects.
    Type: Application
    Filed: December 16, 2013
    Publication date: August 14, 2014
    Applicants: Institut Pasteur, Genticel, Centre National de la Recherche Scientifique, Institut National de la Sante et de la Recherche Medicale
    Inventors: Xavier-Edmond-Edouard PREVILLE, Claude LECLERC, Daniel LADANT, Benedikt TIMMERMAN
  • Patent number: 8637039
    Abstract: The invention relates to a recombinant protein comprising one or several polypeptides bearing one or several epitopes of one or several HPV antigens, said polypeptides being inserted in the same or different permissive sites of an adenylate cyclase (CyaA) protein or of a fragment thereof, wherein said CyaA fragment retains the property of said adenylate cyclase protein to target Antigen Presenting Cells. It also concerns polynucleotides encoding the same. The recombinant protein or the polynucleotide can be used for the design of therapeutic means against HPV infection or against its malignant effects.
    Type: Grant
    Filed: December 23, 2010
    Date of Patent: January 28, 2014
    Assignees: Institut Pasteur, Institut National de la Sante et de la Recherche Medicale, Centre National de la Recherche Scientifique, Genticel
    Inventors: Xavier-Edmond-Edouard Preville, Claude Leclerc, Daniel Ladant, Benedikt Timmerman
  • Patent number: 8628779
    Abstract: The invention relates to a recombinant protein comprising one or several polypeptides bearing one or several epitopes of one or several HPV antigens, said polypeptides being inserted in the same or different permissive sites of an adenylate cyclase (CyaA) protein or of a fragment thereof, wherein said CyaA fragment retains the property of said adenylate cyclase protein to target Antigen Presenting Cells. It also concerns polynucleotides encoding the same. The recombinant protein or the polynucleotide can be used for the design of therapeutic means against HPV infection or against its malignant effects.
    Type: Grant
    Filed: September 8, 2006
    Date of Patent: January 14, 2014
    Assignees: Institut Pasteur, Genticel, Institut National de la Sante et de la Recherche Medicale, Centre National de la Recherche Scientifique
    Inventors: Xavier-Edmond-Edouard Preville, Claude Leclerc, Daniel Ladant, Benedikt Timmerman
  • Publication number: 20110171244
    Abstract: The invention relates to a recombinant protein comprising one or several polypeptides bearing one or several epitopes of one or several HPV antigens, said polypeptides being inserted in the same or different permissive sites of an adenylate cyclase (CyaA) protein or of a fragment thereof, wherein said CyaA fragment retains the property of said adenylate cyclase protein to target Antigen Presenting Cells. It also concerns polynucleotides encoding the same. The recombinant protein or the polynucleotide can be used for the design of therapeutic means against HPV infection or against its malignant effects.
    Type: Application
    Filed: December 23, 2010
    Publication date: July 14, 2011
    Inventors: Xavier-Edmond-Edouard Preville, Claude Leclerc, Daniel Ladant, Benedikt Timmerman
  • Publication number: 20110097337
    Abstract: The present invention relates to a composition for eliciting a specific cytotoxic T lymphocyte (CTL) response against T cell epitopes in a mammal, which comprises a compound provoking lymphocytopenia, a molecule having selective affinity for professional antigen presenting cells (APC), wherein said molecule is associated to said T cell epitope, and optionally, a pharmaceutical acceptable carrier. Advantageously, the composition further contains an adjuvant. Said composition may be used in anti-infections and anti-cancer therapies.
    Type: Application
    Filed: August 31, 2007
    Publication date: April 28, 2011
    Inventors: Xavier Preville, Benedikt Timmerman
  • Patent number: 7651842
    Abstract: The present invention relates to an Immunogenic Complex comprising Ribosomal Complex and Adhesion of a Microbe or Ribosomal Complex and a viral antigen. The Ribosomal Complex is composed of the subunits of ribosomes (50 S and 30 S subunits in bacteria and 60 S and 40 S subunits of eucaryotes), the ribosomal subunits generally retaining sufficient integrity to preserve substantially the double-stranded nature of the large r-RNA's (16 S and 23 S in bacteria; 18 S and 28 S in eukaryotic cytosol) contained in the ribosomal subunits.
    Type: Grant
    Filed: January 4, 2002
    Date of Patent: January 26, 2010
    Assignee: BT Pharma
    Inventor: Benedikt Timmerman
  • Publication number: 20070072266
    Abstract: The invention relates to a recombinant protein comprising one or several polypeptides bearing one or several epitopes of one or several HPV antigens, said polypeptides being inserted in the same or different permissive sites of an adenylate cyclase (CyaA) protein or of a fragment thereof, wherein said CyaA fragment retains the property of said adenylate cyclase protein to target Antigen Presenting Cells. It also concerns polynucleotides encoding the same. The recombinant protein or the polynucleotide can be used for the design of therapeutic means against HPV infection or against its malignant effects.
    Type: Application
    Filed: September 8, 2006
    Publication date: March 29, 2007
    Inventors: Xavier-Edmond-Edouard Preville, Claude Leclerc, Daniel Ladant, Benedikt Timmerman
  • Publication number: 20040115210
    Abstract: The present invention relates to an Immunogenic Complex comprising Ribosomal Complex and Adhesion of a Microbe or Ribosomal Complex and a viral antigen. The Ribosomal Complex is composed of the subunits of ribosomes (50 S and 30 S subunits in bacteria and 60 S and 40 S subunits of eucaryotes), the ribosomal subunits generally retaining sufficient integrity to preserve substantially the double-stranded nature of the large r-RNA's (16 S and 23 S in bacteria; 18 S and 28 S in eukaryotic cytosol) contained in the ribosomal subunits.
    Type: Application
    Filed: July 7, 2003
    Publication date: June 17, 2004
    Inventor: Benedikt Timmerman
  • Publication number: 20040057962
    Abstract: The present invention relates to an immunogenic complex comprising a ribosomal complex of a microbe and a polynucleotide molecule encoding an antigen originating, derived from, or deduced from a microbe or a virus. The Ribosomal Complex is composed of the subunits of ribosomes (50 S and 30 S subunits in bacteria and 60 S and 40 S subunits in eucaryotes), the ribosomal subunits generally retaining sufficient integrity to preserve substantially the double-stranded nature of the large r-RNA's (16 S and 23S in bacteria; 18S and 28S in eukaryotic cytosol) contained in the ribosomal subunits.
    Type: Application
    Filed: July 7, 2003
    Publication date: March 25, 2004
    Inventor: Benedikt Timmerman